Reducing the Pressure
CardiAction PreScreen: A non-invasive (no blood test required) mass population cardiovascular event risk assessment platform. How identifying the unidentified can reduce the impact of Cardiovascular Disease (CVD) on our populations and the health system.
CardiAction ProScreen: An in-person, non-invasive cardiovascular risk assessment performed in pharmacies across Australia and New Zealand. Using advanced biometric telemetry and the CardiAction proprietary dynamic algorithm, ProScreen provides real-time insights into heart and artery health without the need for blood tests or radiation.
Understanding Cardiovascular Disease: Prevention Strategies for a Healthier Life
Cardiovascular disease (CVD) is the #1 cause of death and continues to be responsible for 1/3rd of all deaths worldwide. Responsible for 44,000 deaths annually in Australia and 20 million globally.
80
Deaths Preventable
with early intervention and broader, more accurate screening
Prevention with CardiAction
With CardiAction, Governments and Healthcare services have the power to reduce its impact.
Revolutionizing
Cardiovascular Health with Innovative Screening Solutions.
CardiAction is dedicated to minimizing the effects of cardiovascular disease through advanced, non-invasive screening technology. Discover how our approach empowers individuals to take control of their heart health.
How Our Screening Works
Follow these simple steps to assess your risk.
Biometrics
Get your cardiovascular event risk score
If at risk, patients will be informed to have their CVD status confirmed by a clinician and then to take immediate preventative action.
Proven Accuracy Through Independent Research
CardiAction’s Pre-Screen model is supported by independent studies and proven as a reliable predictor of cardiovascular disease risk in mass screening programs, particularly benefiting communities with restricted access to healthcare.
Griffith University
The Key
Advantages of CardiAction
The CardiAction Risk Score is a dynamic algorithm that integrates key biomarkers such as age, gender, height, waist circumference, heart rate, and blood pressure data. The model incorporates central systolic blood pressure (cSBP), a recognised predictor of cardiovascular events, such as heart attack and stroke.
When using CardiAction PreScreen, cSBP is predicted with approximately ~80% accuracy based on self-reported and estimated biometrics. When using CardiAction ProScreen, cSBP is directly measured with ~99% accuracy in person using Pulse Wave Analysis (PWA). Both methods provide insight into arterial wall stiffness and inflammation. Research has shown that central blood pressure correlates more strongly with vascular disease and clinical outcomes than traditional brachial (arm) blood pressure.
Real Stories, Real Impact
Transforming lives through innovative cardiovascular risk assessment.
